OPKO Diagnostics, a division of OPKO Health, Inc., and Sony DADC have signed a supply agreement for high volume production of a key component of the OPKO Sangia microfluidic cassette.
The Sangia cassettes are designed to perform quantitative immunoassays from a finger-stick blood sample on the Claros in-office analyzer. The test results are reported in the physician's office in 10 minutes. The first two OPKO Sangia tests are for total prostate specific antigen (Total PSA) and Total Testosterone.
Sony DADC BioSciences, the leading OEM supplier of smart polymer-based consumables, is using their ISO 13485 facility in Salzburg, Austria, to manufacture to OPKO Diagnostics' specifications.
"We are pleased to be partnered with Sony DADC, a world leader in high precision consumable manufacturing, for production of Sangia technology components," said David Okrongly, president of OPKO Diagnostics. "It is critical to us that Sony DADC also meets the regulatory demands of our in vitro diagnostic products and is manufacturing to the ISO 13485 quality standard."
"We are delighted to have gained the trust of the team at OPKO Diagnostics. Based on our extensive experience in translating polymer science into robust manufacturing processes, we look forward to supplying the Sangia microfluidic components to OPKO Diagnostics as they grow their global business footprint," said Dr Chris Mauracher, senior vice president of the BioSciences division of Sony DADC.
Building on Sony DADC's experience in high-precision optical disk manufacturing, Sony DADC's BioSciences division partners with Life Sciences and Diagnostics companies enabling the industrial manufacturing of smart polymer parts.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.